Dihexa Research Overview: Mechanism, Dosing Notes & Cognitive Peptide Context

Dihexa research overview: mechanism of action, BDNF-potentiating activity, and preliminary dosing context for this experimental cognitive research compound.

TL;DR — Dihexa at a Glance

• Dihexa (PNB-0408) is a hexapeptide derived from angiotensin IV, designed to cross the blood-brain barrier and potentiate HGF/c-Met receptor signaling
• Mechanism: potentiates hepatocyte growth factor (HGF) at the Met receptor tyrosine kinase, promoting synaptogenesis and dendritic spine formation in hippocampal models
• Dosing context is extrapolated from animal studies (1–10 mg/kg); no human clinical trial data exists — dose estimates are speculative
• Notable for extraordinary preclinical potency compared to BDNF in synaptogenesis assays, but translational evidence to humans is essentially absent

Disclaimer: Dihexa is a research compound not approved by the FDA for human use. All information on this page is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before use.

What Dihexa Is

Calculate your Dihexa reconstitution → Peptide Reconstitution Calculator

Dihexa (also known as PNB-0408, full name N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small hexapeptide derived from angiotensin IV — a metabolite of the angiotensin II system that was found to modulate learning and memory in rodents when administered directly to the brain. Dihexa was developed at Washington State University, primarily in the laboratory of Joseph Harding, as a brain-penetrant, orally bioavailable compound that robustly activates the HGF/c-Met cognitive enhancement pathway.

The compound was designed to cross the blood-brain barrier, a challenge for most peptide compounds. The lipophilic N-hexanoyl modification at the N-terminus is believed to be primarily responsible for BBB penetration and also contributes to its transdermal absorption characteristics.

Dihexa sits at a remarkable intersection of neuropharmacology: it originated in research on the angiotensin system's role in cognition, yet its primary mechanism involves the hepatocyte growth factor (HGF) signaling pathway — more commonly associated with tissue repair and cancer biology than neuroplasticity. The result is a compound with compelling preclinical potency data and essentially no translational human evidence.

Mechanism

The hepatocyte growth factor receptor (Met, also known as c-Met) is a receptor tyrosine kinase that, when activated by HGF, promotes dendritic arborization, axonal growth, and the formation of new dendritic spines and functional synaptic connections (synaptogenesis). In the hippocampus, Met signaling intersects with NMDA receptor-dependent long-term potentiation (LTP), the synaptic mechanism most directly linked to memory encoding.

The landmark McCoy et al. (2013) paper published in the Journal of Clinical Investigation described Dihexa as an "HGF super-agonist" — it potentiates HGF-induced Met signaling rather than activating Met directly. In a dendritic spine density assay, Dihexa was approximately 10^7 times (10 million times) more potent than brain-derived neurotrophic factor (BDNF) at promoting new functional synaptic contacts.

This potency comparison requires context. BDNF and Dihexa act through entirely different receptors (TrkB for BDNF; potentiation of Met for Dihexa), so the comparison is partly mechanistic rather than directly competitive. BDNF has many functions in neural development and maintenance beyond synaptogenesis, while Dihexa's effects appear more narrowly focused on the HGF/Met-dependent component of synaptic plasticity. The potency figure reflects differences in assay sensitivity and receptor-pathway efficiency.

In rodent behavioral models (Morris Water Maze), subcutaneous Dihexa improved spatial learning and reversed pharmacologically-induced cognitive deficits at mid-range doses. A U-shaped dose-response curve was observed — a pattern consistent with receptor-potentiating compounds operating near saturation thresholds. Peripheral administration confirmed CNS penetration, validating the BBB-crossing design.

The HGF/Met pathway that Dihexa activates is also involved in cancer biology — it promotes cell proliferation and survival. This is the primary theoretical safety concern in the absence of long-term carcinogenicity data.

Dosing Context

Important: No human clinical trial data is available for Dihexa. All dosing context is extrapolated from animal studies.

Animal studies used doses of 1–10 mg/kg subcutaneously. Allometric scaling from rat to human using the body surface area method (divide by 6.2) yields a rough human equivalent dose of approximately 0.16–1.6 mg/kg — which for a 70 kg subject would be approximately 11–112 mg. However, the research community commonly discusses much lower doses (1–10 mg) as potentially active, possibly reflecting better human bioavailability than the scaling would predict.

Both oral and transdermal routes have been studied in preclinical models, though subcutaneous provides more predictable absorption kinetics. Because long-term safety data does not exist, short research cycles of 2–4 weeks with extended washout periods are standard practice in preclinical research designs. The unknown long-term profile is the primary limitation on protocol duration.

These dose estimates are speculative and should not be interpreted as clinically validated parameters.

Reconstitution & Dosing Context

Dihexa is typically supplied as a lyophilized powder in vials ranging from 1 mg to 10 mg. Reconstitution with bacteriostatic water is standard practice. The table below shows common vial sizes, recommended BAC water volumes, and the resulting working concentrations used in research contexts.

For any vial size or target dose, use the Peptide Reconstitution Calculator to generate exact syringe markings.

Calculate your Dihexa reconstitution → Peptide Reconstitution Calculator

Research Protocol Notes

Given the absence of human pharmacokinetic data, researchers designing Dihexa protocols rely on a combination of the allometric scaling estimates above and community-observed practice patterns. Several practical considerations apply:

Cycle Length: Most Dihexa research discussions converge on short cycles of 2–4 weeks, with washout periods of at least 4–8 weeks between cycles. The primary rationale is the HGF/Met pathway's involvement in cell proliferation — a theoretical oncology concern that has not been systematically studied in long-duration models. Short cycles represent a pragmatic response to this uncertainty rather than established pharmacological guidance.

Route of Administration: Subcutaneous injection is the most common route, providing predictable absorption and bypassing first-pass metabolism. Transdermal application (via DMSO vehicle) has been discussed in research contexts and is consistent with the compound's lipophilic N-hexanoyl modification, though absorption is less quantifiable. Oral bioavailability in humans remains unstudied directly.

Frequency: Research discussions most often describe daily or every-other-day administration during the active cycle window. Given the absence of established half-life data in humans, researchers typically err toward daily dosing to maintain consistent tissue exposure.

Storage: Lyophilized Dihexa should be stored at -20°C for long-term stability and at 2–8°C for vials in active use. After reconstitution with bacteriostatic water, the solution is typically stable for 4–6 weeks at 2–8°C. Avoid repeated freeze-thaw cycles of reconstituted solution and protect from light during handling.

Co-administration Context: For researchers interested in broader cognitive enhancement stacks, Dihexa is sometimes considered alongside established compounds such as Semax or Selank, which have substantially more documented human use. See the Semax vs. Selank comparison for context on the evidence base of other nootropic peptides.

Research Status

Dihexa remains entirely preclinical. No Phase 1 human safety data has been published. The intellectual property is held by Washington State University. The primary published evidence comes from Harding's laboratory and has not been independently replicated at scale. Independent replication is the standard of evidence that Dihexa has not yet met.

The theoretical oncology concern — that chronic HGF/Met pathway activation could promote pre-existing tumor growth — has not been systematically studied in long-duration models. The short-cycle dosing conventions common in Dihexa research discussions are partly motivated by this concern. Absence of observed tumor formation in short-duration rodent studies does not establish long-term safety.

For researchers prioritizing established safety profiles, Semax and Selank offer considerably more human evidence from decades of clinical use in Russia — see the Semax vs. Selank overview for a direct comparison. The nootropics research hub provides an organized overview of cognitive compounds at varying stages of evidence.

Frequently Asked Questions

Q: What makes dihexa different from other nootropic peptides? A: Dihexa's mechanism (HGF/Met potentiation for synaptogenesis) is entirely distinct from other nootropic peptides. Semax upregulates BDNF and modulates monoamine systems. Selank has GABAergic and anxiolytic effects. Dihexa acts on the HGF/Met axis with extraordinary preclinical potency relative to BDNF. What makes it unusual is the combination of this dramatic preclinical data alongside essentially zero human translational evidence — the largest potency claims alongside the weakest human data of any commonly discussed nootropic peptide. Researchers comparing cognitive enhancement options should weigh Dihexa's potency claims against its near-total absence of human safety data.

Q: Is dihexa available as a research compound? A: Dihexa has been available through peptide research suppliers as a research compound. Its regulatory status as a research chemical means it can be sold for laboratory research purposes in the United States. It is not approved for human use anywhere. Researchers should be aware that quality control and purity can vary between suppliers, which is particularly relevant for a compound where no established dosing framework exists.

Q: What research has been done on dihexa? A: The core published evidence comes from McCoy et al. (2013) in the Journal of Clinical Investigation, reporting synaptogenic activity in rodent models and the potency comparison to BDNF. Additional rodent studies from Harding's group examined cognitive deficits in scopolamine-impaired rats and Alzheimer's disease models. These results have not been independently replicated in separate laboratories. No human clinical trials have been conducted or registered.

→ Browse Nootropic Peptides

All content is for educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions